Dr. Marino on Transforming Skin Surgery With Personalized Tissue

In this Pharmaceutical Executive interview, Daniela Marino, PhD, Co-founder and CEO of CUTISS, talks about her involvement in supporting the development of denovoSkin™, an autologous, bio-engineered dermo-epidermal skin graft. Currently in late-stage clinical trials, denovoSkin™ aims to improve outcomes for patients requiring skin reconstruction. Early results suggest it may offer advantages over traditional autografting, the current standard of care, particularly in reducing donor site morbidity and improving aesthetic and functional results. The full clinical development program can be viewed online here.

00:52 – Transitioning from academia to biotech to chase a dream and unlock discoveries in regenerative medicine.

3:20 – Considering both “deep science” and “deep tech” to advance skin tissue therapeutics, regenerative medicine, tissue engineering, and skin pigmentation.

5:17 – Understanding the clinical benefits of denovoSkin™ over standard of care treatment for skin surgery.

7:50 – Focusing on utilizing cutting-edge automation to revolutionize skin surgery and advance dermatology through personalized tissue therapies.

10:33 – Preparing for market access of denovoSkin™.

12:00 – Identifying new opportunities in regenerative medicine, based on personal experience.

13:37 – Predicting the future of skin engineering using autologous, bio-engineered dermo-epidermal skin grafting and lessons learned along a journey to revolutionize skin surgery.